220 related articles for article (PubMed ID: 10346884)
1. Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors.
Kurihara A; Deguchi Y; Pardridge WM
Bioconjug Chem; 1999; 10(3):502-11. PubMed ID: 10346884
[TBL] [Abstract][Full Text] [Related]
2. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker.
Deguchi Y; Kurihara A; Pardridge WM
Bioconjug Chem; 1999; 10(1):32-7. PubMed ID: 9893961
[TBL] [Abstract][Full Text] [Related]
3. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology.
Suzuki T; Wu D; Schlachetzki F; Li JY; Boado RJ; Pardridge WM
J Nucl Med; 2004 Oct; 45(10):1766-75. PubMed ID: 15471847
[TBL] [Abstract][Full Text] [Related]
4. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier.
Kurihara A; Pardridge WM
Cancer Res; 1999 Dec; 59(24):6159-63. PubMed ID: 10626807
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of systemically administered radiolabeled epidermal growth factor as a brain tumor targeting agent.
Yang W; Barth RF; Leveille R; Adams DM; Ciesielski M; Fenstermaker RA; Capala J
J Neurooncol; 2001 Oct; 55(1):19-28. PubMed ID: 11804279
[TBL] [Abstract][Full Text] [Related]
6. Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.
Saito Y; Buciak J; Yang J; Pardridge WM
Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10227-31. PubMed ID: 7479757
[TBL] [Abstract][Full Text] [Related]
7. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease).
Jeong Lee H; Pardridge WM
J Drug Target; 2000; 8(6):413-24. PubMed ID: 11328667
[TBL] [Abstract][Full Text] [Related]
8. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeling of epidermal growth factor with 99mTc and in vivo localization following intracerebral injection into normal and glioma-bearing rats.
Capala J; Barth RF; Bailey MQ; Fenstermaker RA; Marek MJ; Rhodes BA
Bioconjug Chem; 1997; 8(3):289-95. PubMed ID: 9177833
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
11. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas.
Yang W; Barth RF; Adams DM; Ciesielski MJ; Fenstermaker RA; Shukla S; Tjarks W; Caligiuri MA
Cancer Res; 2002 Nov; 62(22):6552-8. PubMed ID: 12438250
[TBL] [Abstract][Full Text] [Related]
12. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration.
Pardridge WM; Wu D; Sakane T
Pharm Res; 1998 Apr; 15(4):576-82. PubMed ID: 9587954
[TBL] [Abstract][Full Text] [Related]
13. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system.
Wu D; Pardridge WM
J Pharmacol Exp Ther; 1996 Oct; 279(1):77-83. PubMed ID: 8858978
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Kang YS; Bickel U; Pardridge WM
Drug Metab Dispos; 1994; 22(1):99-105. PubMed ID: 8149897
[TBL] [Abstract][Full Text] [Related]
15. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225.
Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C
J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869
[TBL] [Abstract][Full Text] [Related]
16. Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111)In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections.
Kurihara A; Pardridge WM
Bioconjug Chem; 2000; 11(3):380-6. PubMed ID: 10821654
[TBL] [Abstract][Full Text] [Related]
17. Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate.
Kang YS; Pardridge WM
J Pharmacol Exp Ther; 1994 Apr; 269(1):344-50. PubMed ID: 8169841
[TBL] [Abstract][Full Text] [Related]
18. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy.
Wu G; Barth RF; Yang W; Chatterjee M; Tjarks W; Ciesielski MJ; Fenstermaker RA
Bioconjug Chem; 2004; 15(1):185-94. PubMed ID: 14733599
[TBL] [Abstract][Full Text] [Related]
19. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor.
Wu D; Yang J; Pardridge WM
J Clin Invest; 1997 Oct; 100(7):1804-12. PubMed ID: 9312181
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system.
Wu D; Song BW; Vinters HV; Pardridge WM
J Drug Target; 2002 May; 10(3):239-45. PubMed ID: 12075825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
